1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today 
to enhance your projects.
| Species | Canine  | 
                
| Cat.No | ABC-H0096X  | 
                
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi.  | 
                
| Product Category | Primary Cells | 
| Size/Quantity | 1 vial  | 
                
| Cell Type | DC Cell  | 
                
| Shipping Info | Dry Ice  | 
                
| Growth Conditions | 37 ℃, 5% CO2  | 
                
| Source Organ | Bone Marrow  | 
                
| Disease | Normal  | 
                
| Biosafety Level | 1  | 
                
| Storage | Liquid Nitrogen  | 
                
| Product Type | Canine Primary Cells  | 
                
Canine Bone Marrow Dendritic Cells are primary immune cells isolated from the femurs and tibias of healthy male and female beagle dogs. In vitro, they are non-adherent and short-lived. They are derived from hematopoietic progenitors and differentiated using GM-CSF or Flt3L. Cells express CD4, CD8, CD1c, CD11b, CD11c, and CD14, detected by flow cytometry or immunofluorescence. LPS stimulation induces MHC-II and co-stimulatory molecule expression. Karyotype analysis has not been reported. They are non-tumorigenic and non-metastatic, free of Mycoplasma, bacteria, fungi, yeast, and tested negative for canine-specific viruses like CDV and CAV. These cells are ideal for veterinary immunology and translational antigen-presentation studies under BSL-2 conditions.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Canine Bone Marrow Dendritic Cells (caDC) are valuable for investigating immune-mediated diseases, graft rejections, and cancers in canine models for immune-mediated diseases, graft rejections, and cancers. Characterizing caDC subsets and their role in inflammation and immune responses is crucial for advancing veterinary immunology.Furthermore, they show promise as a novel immunotherapy for canine cancers, as they can be induced to stimulate tumor-specific CD8 T cells, opening avenues for innovative and targeted therapeutic approaches in veterinary oncology.